Immuno-oncology Product Solutions

Accelerate Cancer Immunotherapeutic Discovery and Development with Cell-based, Clinically Relevant Assays

Immuno-oncology (IO) is a class of treatment modality designed to augment the body’s natural immune defense against cancer. The IO space is currently dominated by therapeutics development programs targeting immune checkpoint modulators and cytokines as these molecules hold significant promise in cancer therapy. Another key modality is the modulation of Fc-mediated effector mechanisms of therapeutic antibodies, including ADCC, ADCP, CAR-T, CAR-NK, CDC, and other cytotoxicity-focused applications.

Eurofins DiscoverX® offers the most comprehensive product portfolio of cell lines, cell pools, eXpress™ assay kits, and bioassay kits to enable fast, effective, and clinically relevant understanding of IO targets, their pathways, and mechanisms to empower quicker development of IO therapeutics. Continuous culture cell lines allow for full-scale interrogation, screening, and profiling of IO therapeutic MOAs (mechanism of actions), while the ready-to-use qualified bioassays are developed to meet the industry requirements and regulatory expectations. Eurofins DiscoverX offers fast and seamless implementation for IO therapeutic MOA confirmation, stability studies, and potency testing in QC lot release programs as a thaw-and-assay platform.

Learn how you can rapidly screen and develop small molecules, biologics (peptides, antibodies, or bispecific antibodies), or cellular therapies for your IO drug discovery and development program.

Product Highlights
  • MOA-reflective Assays – Designed for regulatory acceptance, these assays are intended to interrogate specific target biology for fast implementation through discovery, validation, characterization, and development stages of an intended therapeutic
  • Broad Coverage of Checkpoint Modulators – Industry’s most comprehensive menu of stable cell lines and ready-to-use bioassays for targets including PD-1, SIRPα, CTLA4, OX40, ICOS, and many others
  • Comprehensive Cytokine Receptor Assays – Functional assays for >85% of human interleukins receptors as well as cytokine-like interleukins, GM-CSF, interferons, chemokines, TNFα, TGF-β, and Ig superfamily receptor types
  • Specific Cytotoxicity Assays – Specifically measure direct target cell death in co-cultures using relevant immune effector cells with KILR® cytotoxicity assays for ADCC, ADCP, CAR-T, T cell redirection, and adoptive T cell therapy

Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.

SHOP PRODUCTSALL TARGETS LISTREAD WHITE PAPERIMMUNOTHER. EBOOK

Products

Fast-track your IO drug discovery and development with physiologically relevant cell-based assays. Eurofins DiscoverX offers the most comprehensive portfolio of cell-based assays to enable fast, effective, and clinically relevant understanding of IO to interrogate targets, pathways, and mechanisms to empower quicker development of IO therapeutics.
 

Product Types

  • Immuno-oncology Bioassay Kits - Ready-to-use cell-based assay kits with a simple, homogenous protocol and are provided as qualified or target-based. These physiologically relevant, robust bioassays are fit-for-purpose for use in screening and characterization applications to potency testing in quality control lot-release programs. Learn more about Bioassay Kits.
  • Immuno-oncology eXpress Assay Kits - Ready-to-use cell-based assay kits for quick analysis and implementation in early discovery phases for screening applications, proof-of-concept, mechanism of action confirmation, and rank-ordering studies. Learn more about eXpress Assay Kits.
  • Immuno-oncology Cell Lines - Stable cell lines developed to reflect the target’s mechanism of action with a drug interaction in a standard cell line background. Learn more about Stable Cell Lines.
  • Immuno-oncology Recombinant Proteins - Recombinant human, mouse, rat, and other proteins expressed in E. coli, mammalian cell lines, or Sf21 insect cells; tagged (e.g. GST, His6); and used in screening and profiling services. Learn more about Recombinant Proteins.

Applications

  • KILR® Cytotoxicity Assays – Non-radioactive, dye-free cytotoxicity assays to specifically measure targeted cell death in a co-culture with immune effector cells. Assays are designed to detect cancer cell death for applications like ADCC, CDC, ADCP, T cell redirection and CAR-T
  • Checkpoint Receptor Assays – MOA-reflective functional assays enabling characterization, screening, lead optimization, and potency assay development of small molecule and biologic drugs for co-stimulatory and inhibitory checkpoint receptors. Assays include signaling; receptor dimerization, internalization, and clustering; and bispecific antibody development modalities
  • Cytokine Receptor Assays – Cell-based assays for characterization, functional screening, QC lot-release testing, and neutralizing antibody studies of drugs targeting cytokine/interleukin receptors. Assays include receptor dimerization, SH2 recruitment, IkB degradation, β-arrestin recruitment, and STAT3 transcriptional reporter mechanisms
  • Signaling Reporter Assays – Orthogonal, functional cell-based assays with a downstream read-out used for screening and quantifying activation and inhibition of various signaling pathways